Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI signs ten-target DART alliance with MacroGenics

Executive Summary

In one of two Big Pharma deals it signed on the same day, biologics developer MacroGenics Inc. has agreed to work with Boehringer Ingelheim GMBH on antibody-like molecules against up to ten combinations of targets, initially for immune disorders and potentially extending to cancer and respiratory, cardio-metabolic, and infectious diseases. The candidates will be generated by MacroGenics' Dual-Affinity Re-Targeting (DART) technology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies